Department of Orthopedics, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China.
Laboratory of New Techniques of Restoration & Reconstruction of Orthopedics and Traumatology, Nanjing University of Chinese Medicine, Nanjing, China.
BMC Musculoskelet Disord. 2023 May 18;24(1):394. doi: 10.1186/s12891-023-06488-6.
Chronic musculoskeletal pain (CMP) is a complex condition that is mainly treated with analgesic drugs. However, antidepressant intervention is also an important factor in the treatment of CMP. Duloxetine is an effective treatment option for patients with CMP as its antidepressant effect. The purpose of this article is to evaluate the efficacy and safety of duloxetine in treating CMP.
We searched PubMed, Web of Science, Embase, Cochrane Library from inception to May, 2022. Randomized controlled trials (RCTs) evaluating the efficacy and safety of duloxetine versus placebo in patients with CMP were included. We identified 13 articles and studied a population of 4201 participants in 4 countries.
This meta-analysis showed that the duloxetine has statistically significant compared with the placebo control, benefits on 24-hour average pain, living quality, physical function, and global impressions and there was no difference in the incidence of serious adverse event. In general, duloxetine can improve mood and pain level at the same time.
This review shows a significant contribution of duloxetine to CMP symptom relief. This meta-analysis improved that duloxetine can significantly reduce the pain level of patients, improve depressive symptoms and global impression, and has no obvious serious adverse reactions. However, additional studies are required to confirm the relationship between psychological diseases and chronic pain and explore their internal links.
慢性肌肉骨骼疼痛（CMP）是一种复杂的疾病，主要采用镇痛药物进行治疗。然而，抗抑郁药物干预也是 CMP 治疗的重要因素。度洛西汀作为一种有效的抗抑郁药物，是治疗 CMP 患者的选择之一。本文旨在评估度洛西汀治疗 CMP 的疗效和安全性。
我们检索了PubMed、Web of Science、Embase、Cochrane Library 从建库到 2022 年 5 月的相关文献。纳入评估度洛西汀与安慰剂治疗 CMP 患者疗效和安全性的随机对照试验（RCT）。我们共识别出 13 篇文章，涉及来自 4 个国家的 4201 名参与者。
荟萃分析显示，度洛西汀与安慰剂相比在 24 小时平均疼痛、生活质量、躯体功能和整体印象方面具有统计学意义，且严重不良事件的发生率无差异。总体而言，度洛西汀可以同时改善情绪和疼痛水平。
本综述表明度洛西汀对 CMP 症状缓解有显著作用。该荟萃分析表明，度洛西汀能显著降低患者的疼痛水平，改善抑郁症状和整体印象，且无明显严重不良反应。然而，还需要更多的研究来证实心理疾病与慢性疼痛之间的关系，并探索它们的内在联系。
